Lifecycle status Grey Sky Venture Partners appears to be a halted investor in life sciences startups as of 2021 and is not making new investments, indicating outbound effort should target former portfolio relationships, potential LPs, or successor funds rather than seeking new deal introductions.

Portfolio signals Past investments include Inflammatix, Modulated Imaging, and Winterlight Labs, signaling a focus on diagnostics, imaging tech, and cognitive health analytics; sales opportunities may lie in follow-on funding rounds, strategic partnerships, or technology licensing with these or similar portfolios.

Funding history Active participation in mid to late-stage rounds (Series A to Series C) suggests GSVP engaged in substantial capital infusions; potential engagement targets could include founders or co-investors from these rounds seeking additional capital sources or exit planning guidance.

Tech affinity GSVP’s tech stack and emphasis on life sciences startups indicate receptivity to technology-driven ventures; outreach could emphasize data analytics, AI-driven diagnostics, and cloud-based platforms aligned with the portfolio’s product areas.

Engagement gaps With very limited current staffing and no ongoing investments, there may be an opportunity to position service or advisory offerings tailored to early-stage life sciences founders, academic spinouts, or portfolio follow-ons needing strategic introductions, grant support, or regulatory diligence assistance.